MDPV, a potent synthetic cathinone, is rapidly absorbed after subcutaneous injection in male Wistar rats, reaching peak concentrations in serum, brain, and lungs within 30 minutes. It readily crosses the blood-brain barrier, with a brain-to-serum ratio of about 2 lasting for roughly 120 minutes. The drug is primarily excreted as metabolites, with demethylenyl-MDPV and demethylenyl-methyl-MDPV levels three to four times higher than the parent drug in urine. MDPV acts as a typical stimulant, producing locomotor activation, disrupted spatial behavior, moderate hyperthermia (exacerbated in group-housed animals), and transient disruption of prepulse inhibition at 4 mg/kg, consistent with a dopaminergic mechanism. No specific signs of acute toxicity were observed at the doses used.
Methoxetamine, a designer drug sold as a substitute for the dissociative anesthetic ketamine, has been linked to numerous hospital intoxications and deaths across Europe.
The drug 5,6-Methylenedioxy-2-aminoindane (MDAI), a serotoninergic aminoindane sold as a substitute for banned stimulants and entactogens, is metabolized in rats primarily through oxidative demethylenation followed by O-methylation and N-acetylation, producing five main metabolites found as glucuronides and sulphates. Most of the administered MDAI was excreted unchanged. Minor metabolites formed by hydroxylation include cis- and trans-1-hydroxy- and 4-hydroxy derivatives. Identification of most metabolites was confirmed with synthesized reference standards.
The X-ray powder diffraction pattern of 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one hydrochloride is reported, providing its unit-cell parameters and space group. The compound crystallizes in the monoclinic space group P21 with two molecules per unit cell. All observed diffraction lines were indexed and matched this space group, and no impurities were detected.